HK1047702A1 - 用与cd20结合的拮抗剂阻断对外来抗原的免疫应答 - Google Patents

用与cd20结合的拮抗剂阻断对外来抗原的免疫应答 Download PDF

Info

Publication number
HK1047702A1
HK1047702A1 HK02109138.2A HK02109138A HK1047702A1 HK 1047702 A1 HK1047702 A1 HK 1047702A1 HK 02109138 A HK02109138 A HK 02109138A HK 1047702 A1 HK1047702 A1 HK 1047702A1
Authority
HK
Hong Kong
Prior art keywords
immune response
antagonist
binds
foreign antigen
blocking immune
Prior art date
Application number
HK02109138.2A
Other languages
English (en)
Chinese (zh)
Inventor
J. Grillo-Lopez Antonio
A. Kunkel Lori
A. Stewart Timothy
Original Assignee
Genentech Inc.
Idec Pharmaceuticals Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc., Idec Pharmaceuticals Corporation filed Critical Genentech Inc.
Publication of HK1047702A1 publication Critical patent/HK1047702A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
HK02109138.2A 1999-07-12 2000-07-10 用与cd20结合的拮抗剂阻断对外来抗原的免疫应答 HK1047702A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US144405P 1998-08-31
US14440599P 1999-07-12 1999-07-12
PCT/US2000/018776 WO2001003734A1 (en) 1999-07-12 2000-07-10 Blocking immune response to a foreign antigen using an antagonist which binds to cd20

Publications (1)

Publication Number Publication Date
HK1047702A1 true HK1047702A1 (zh) 2003-03-07

Family

ID=22508442

Family Applications (1)

Application Number Title Priority Date Filing Date
HK02109138.2A HK1047702A1 (zh) 1999-07-12 2000-07-10 用与cd20结合的拮抗剂阻断对外来抗原的免疫应答

Country Status (17)

Country Link
US (1) US20100003252A1 (https=)
EP (1) EP1216056A1 (https=)
JP (1) JP2003528805A (https=)
KR (2) KR20080075044A (https=)
CN (2) CN101264324A (https=)
AU (2) AU778863B2 (https=)
BR (1) BR0013201A (https=)
CA (1) CA2379274A1 (https=)
HK (1) HK1047702A1 (https=)
HU (1) HUP0202238A3 (https=)
IL (1) IL147547A0 (https=)
MX (1) MXPA02000419A (https=)
NO (1) NO20020128L (https=)
NZ (1) NZ516491A (https=)
PL (1) PL201086B1 (https=)
WO (1) WO2001003734A1 (https=)
ZA (1) ZA200200272B (https=)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA01011279A (es) 1999-05-07 2002-07-02 Genentech Inc Tratamiento de enfermedades autoinmunes con antagonistas que se unene a los marcadores de superficie, de celulas b.
US7097840B2 (en) * 2000-03-16 2006-08-29 Genentech, Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
NZ533933A (en) * 2002-01-02 2008-06-30 Genentech Inc Compositions and methods for the diagnosis and treatment of glioma tumor
SI1545613T1 (sl) * 2002-07-31 2011-11-30 Seattle Genetics Inc Avristatinski konjugati in njihova uporaba za zdravljenje raka avtoimunske bolezni ali infekcijskebolezni
CN101928344B (zh) 2002-10-17 2014-08-13 根马布股份公司 抗cd20的人单克隆抗体
EP3263596A1 (en) 2002-12-16 2018-01-03 Genentech, Inc. Immunoglobulin variants and uses thereof
EP2062916A3 (en) 2003-04-09 2009-08-19 Genentech, Inc. Therapy of autoimmune disease in a patient with an inadequate response to a TNF-Alpha inhibitor
CA2525251C (en) 2003-05-09 2015-10-27 Duke University Cd20-specific antibodies and methods employing same
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
PL1631313T3 (pl) 2003-06-05 2015-08-31 Genentech Inc Terapia skojarzona zaburzeń z komórek B
KR20060132554A (ko) * 2003-08-29 2006-12-21 제넨테크, 인크. 안과 질병의 항-ｃｄ２０ 치료
ES2672640T3 (es) 2003-11-05 2018-06-15 Roche Glycart Ag Moléculas de unión a antígeno con afinidad de unión a receptores Fc y función efectora incrementadas
MXPA06006865A (es) * 2003-12-19 2006-08-23 Genentech Inc Deteccion de cd20 en rechazo de transplante.
WO2005103081A2 (en) 2004-04-20 2005-11-03 Genmab A/S Human monoclonal antibodies against cd20
TW201422238A (zh) 2004-06-04 2014-06-16 Genentech Inc Ｃｄ２０抗體於治療多發性硬化症之用途及用於該用途之物品
PL1776384T3 (pl) 2004-08-04 2013-10-31 Mentrik Biotech Llc WARIANTY REGIONÓW Fc
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
ATE460672T1 (de) 2005-05-20 2010-03-15 Genentech Inc Vorbehandlung einer biologischen probe aus einem individuum mit autoimmunkrankheit
HRP20140338T1 (hr) 2005-07-25 2014-06-20 Emergent Product Development Seattle, Llc Smanjenje broja b-stanica upotrebom molekula koje se specifiäśno vežu na cd37 i cd20
JP2009502936A (ja) 2005-07-25 2009-01-29 トルビオン ファーマシューティカルズ， インコーポレイテッド Ｃｄ２０特異的結合分子の単一投与量
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
WO2007062090A2 (en) 2005-11-23 2007-05-31 Genentech, Inc. Methods and compositions related to b cell assays
WO2007146968A2 (en) 2006-06-12 2007-12-21 Trubion Pharmaceuticals, Inc. Single-chain multivalent binding proteins with effector function
KR20190140090A (ko) 2007-07-09 2019-12-18 제넨테크, 인크. 폴리펩티드의 재조합 생산 동안의 디술피드 결합 환원의 방지
CN101113459A (zh) * 2007-07-16 2008-01-30 东莞太力生物工程有限公司 一种重组复制缺陷型病毒、含有该病毒的药物组合物及其应用
EP2200631A1 (en) 2007-10-16 2010-06-30 Zymogenetics, Inc. Combination of blys inhibition and anti-cd 20 agents for treatment of autoimmune disease
US7914785B2 (en) 2008-01-02 2011-03-29 Bergen Teknologieverforing As B-cell depleting agents, like anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
EP2077281A1 (en) 2008-01-02 2009-07-08 Bergen Teknologioverforing AS Anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
EP2365003A1 (en) 2008-04-11 2011-09-14 Emergent Product Development Seattle, LLC CD37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
TW201014605A (en) 2008-09-16 2010-04-16 Genentech Inc Methods for treating progressive multiple sclerosis
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
CN104059955A (zh) 2009-08-11 2014-09-24 弗·哈夫曼-拉罗切有限公司 在无谷氨酰胺的细胞培养基中的蛋白质生产
NZ716587A (en) * 2009-11-11 2017-10-27 Ganymed Pharmaceuticals Ag Antibodies specific for claudin 6 (cldn6)
TW201129384A (en) 2010-02-10 2011-09-01 Immunogen Inc CD20 antibodies and uses thereof
US20170049887A1 (en) * 2014-04-25 2017-02-23 University Of Florida Research Foundation, Inc. Methods of permitting a subject to receive multiple doses of recombinant adeno-associated virus
AU2016271124C1 (en) 2015-05-30 2020-05-14 Molecular Templates, Inc. De-immunized, Shiga toxin a subunit scaffolds and cell-targeting molecules comprising the same
MX391086B (es) 2015-06-24 2025-03-21 Hoffmann La Roche Anticuerpos anti-receptor de transferrina con afinidad diseñada.
EP3352760B1 (en) 2015-09-21 2026-03-11 Aptevo Research and Development LLC Cd3 binding polypeptides
NZ741067A (en) 2015-10-02 2023-07-28 Hoffmann La Roche Bispecific anti-human cd20/human transferrin receptor antibodies and methods of use
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
EP4026848A1 (en) * 2015-12-09 2022-07-13 F. Hoffmann-La Roche AG Type ii anti-cd20 antibody for reducing the cytokine release syndrome
KR20240102971A (ko) 2021-11-16 2024-07-03 제넨테크, 인크. 모수네투주맙을 이용하여 전신 홍반성 루푸스(sle)를 치료하기 위한 방법과 조성물

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5672347A (en) * 1984-07-05 1997-09-30 Genentech, Inc. Tumor necrosis factor antagonists and their use
IL85035A0 (en) * 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US4975278A (en) * 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US5506126A (en) * 1988-02-25 1996-04-09 The General Hospital Corporation Rapid immunoselection cloning method
US4861579A (en) * 1988-03-17 1989-08-29 American Cyanamid Company Suppression of B-lymphocytes in mammals by administration of anti-B-lymphocyte antibodies
IE922437A1 (en) * 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
US5686072A (en) * 1992-06-17 1997-11-11 Board Of Regents, The University Of Texas Epitope-specific monoclonal antibodies and immunotoxins and uses thereof
US5397703A (en) * 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
US5540926A (en) * 1992-09-04 1996-07-30 Bristol-Myers Squibb Company Soluble and its use in B cell stimulation
US5736137A (en) * 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
MD1367C2 (ro) * 1992-11-13 2000-11-30 Idec Pharmaceuticals Corporation Metode de tratament al limfomului celulelor B, anticorpi anti-CD20, hibridom.
US5484892A (en) * 1993-05-21 1996-01-16 Dana-Farber Cancer Institute, Inc. Monoclonal antibodies that block ligand binding to the CD22 receptor in mature B cells
US5417972A (en) * 1993-08-02 1995-05-23 The Board Of Trustees Of The Leland Stanford Junior University Method of killing B-cells in a complement independent and an ADCC independent manner using antibodies which specifically bind CDIM
US5595721A (en) * 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
US5795569A (en) * 1994-03-31 1998-08-18 Amgen Inc. Mono-pegylated proteins that stimulate megakaryocyte growth and differentiation
US5587459A (en) * 1994-08-19 1996-12-24 Regents Of The University Of Minnesota Immunoconjugates comprising tyrosine kinase inhibitors
WO1996031229A1 (en) * 1995-04-05 1996-10-10 Beth Israel Hospital Association Inhibiting rejection of a graft
US6113898A (en) * 1995-06-07 2000-09-05 Idec Pharmaceuticals Corporation Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies
US5877299A (en) * 1995-06-16 1999-03-02 Stemcell Technologies Inc. Methods for preparing enriched human hematopoietic cell preparations
DK81095A (da) * 1995-07-11 1997-01-12 Henrik S Thomsen Peroralt MR-kontraststof til lever og øvre tarmkanal
US20010056066A1 (en) * 1996-07-26 2001-12-27 Smithkline Beecham Corporation Method of treating immune cell mediated systemic diseases
EP0938334A4 (en) * 1996-07-26 2004-12-15 Smithkline Beecham Corp IMPROVED METHOD FOR TREATING IMMUNE-MEDIATED SYSTEMIC DISEASES
GB2323386A (en) * 1997-03-20 1998-09-23 Procter & Gamble Effervescent detergent granules
US6306393B1 (en) * 1997-03-24 2001-10-23 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
US6171586B1 (en) * 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
AU8296098A (en) * 1997-07-08 1999-02-08 Board Of Regents, The University Of Texas System Compositions and methods for homoconjugates of antibodies which induce growth arrest or apoptosis of tumor cells
US6194551B1 (en) * 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6242195B1 (en) * 1998-04-02 2001-06-05 Genentech, Inc. Methods for determining binding of an analyte to a receptor
US6528624B1 (en) * 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
CA2340091C (en) * 1998-08-11 2013-02-05 Idec Pharmaceuticals Corporation Combination therapies for b-cell lymphomas comprising administration of anti-cd20 antibody
US6224866B1 (en) * 1998-10-07 2001-05-01 Biocrystal Ltd. Immunotherapy of B cell involvement in progression of solid, nonlymphoid tumors
WO2000023573A2 (en) * 1998-10-20 2000-04-27 City Of Hope Cd20-specific redirected t cells and their use in cellular immunotherapy of cd20+ malignancies
US6498181B1 (en) * 1999-01-06 2002-12-24 Maxim Pharmaceuticals Synergistic tumorcidal response induced by histamine
EP1035172A3 (en) * 1999-03-12 2002-11-27 Fuji Photo Film Co., Ltd. Azomethine compound and oily magenta ink
CA2375912C (en) * 1999-06-09 2014-03-11 Immunomedics, Inc. Immunotherapy of autoimmune disorders using antibodies which target b-cells
DE19930748C2 (de) * 1999-07-02 2001-05-17 Infineon Technologies Ag Verfahren zur Herstellung von EEPROM- und DRAM-Grabenspeicherzellbereichen auf einem Chip
US20020006404A1 (en) * 1999-11-08 2002-01-17 Idec Pharmaceuticals Corporation Treatment of cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
CN1981868A (zh) * 2000-03-31 2007-06-20 拜奥根Idec公司 抗细胞因子抗体或拮抗剂与抗－cd20在b细胞淋巴瘤治疗中的联合应用
CN101289511A (zh) * 2000-04-11 2008-10-22 杰南技术公司 多价抗体及其应用
AU5914201A (en) * 2000-04-25 2001-11-07 Idec Pharma Corp Intrathecal administration of rituximab for treatment of central nervous system lymphomas
AU2001270134B2 (en) * 2000-06-22 2006-06-15 University Of Iowa Research Foundation Methods for enhancing antibody-induced cell lysis and treating cancer
IL157946A0 (en) * 2001-04-02 2004-03-28 Genentech Inc Combination therapy
KR101033196B1 (ko) * 2002-02-14 2011-05-09 이뮤노메딕스, 인코오포레이티드 항-ｃｄ20 항체 및 그 융합 단백질 및 이들의 이용방법
EP3263596A1 (en) * 2002-12-16 2018-01-03 Genentech, Inc. Immunoglobulin variants and uses thereof
EP2062916A3 (en) * 2003-04-09 2009-08-19 Genentech, Inc. Therapy of autoimmune disease in a patient with an inadequate response to a TNF-Alpha inhibitor
WO2005044998A2 (en) * 2003-11-05 2005-05-19 Palingen, Inc. Enhanced b cell cytotoxicity of cdim binding antibody

Also Published As

Publication number Publication date
HUP0202238A3 (en) 2004-05-28
HUP0202238A2 (en) 2002-10-28
WO2001003734A1 (en) 2001-01-18
AU778863B2 (en) 2004-12-23
KR20080075044A (ko) 2008-08-13
MXPA02000419A (es) 2004-09-10
AU2005201189A1 (en) 2005-04-14
NZ516491A (en) 2004-11-26
US20100003252A1 (en) 2010-01-07
AU2005201189B2 (en) 2008-04-03
PL352758A1 (en) 2003-09-08
BR0013201A (pt) 2002-04-30
PL201086B1 (pl) 2009-03-31
KR20020027490A (ko) 2002-04-13
CA2379274A1 (en) 2001-01-18
IL147547A0 (en) 2002-08-14
CN1373672A (zh) 2002-10-09
EP1216056A1 (en) 2002-06-26
JP2003528805A (ja) 2003-09-30
ZA200200272B (en) 2003-03-26
CN101264324A (zh) 2008-09-17
AU6082500A (en) 2001-01-30
NO20020128L (no) 2002-02-28
NO20020128D0 (no) 2002-01-11

Similar Documents

Publication Publication Date Title
HK1047702A1 (zh) 用与cd20结合的拮抗剂阻断对外来抗原的免疫应答
CA2235269A1 (en) Monoclonal antibody br110 and uses thereof
HUP0300841A3 (en) Agonist anti-trk-c monoclonal antibodies
SI1546734T1 (sl) N-11 skrajšana amiloid beta monoklonska protitelesa, sestavki, postopki in uporaba
EP1378525A3 (en) Humanized antibodies that bind to the antigen bound by antibody NR-LU-13 and their use in pretargeting methods
WO2002030460A3 (en) Therapeutic antibodies
WO2002016401A3 (en) Monoclonal antibody ds6, tumor-associated antigen ca6, and methods of use thereof
CA2406240A1 (en) Hcv anti-core monoclonal antibodies
WO2006031653A3 (en) Humanized anti-5t4 antibodies and anti-5t4 antibody / calicheamicin conjugates
NO924279D0 (no) Lyofilisert, monoklonalt antistoffpreparat
EP1651659A4 (en) METHOD FOR HUMANIZATION OF MONOCLONAL RABBIT ANTIBODIES
DE60222658D1 (de) Monoklonaler anti-cd-40-antikörper
FI963004L (fi) Vasta-aineen muodostumista kiihottavia monoklonaalivasta-aineita
HUP0302376A3 (en) Anti-tnf antibodies, compositions, methods and uses
PL372803A1 (en) Anti-human tenascin monoclonal antibody
AU5249501A (en) Synthetic peptides that bind to the hepatitis b virus core and e antigens
AU2003285540A1 (en) Antibody for the thyrotropin receptor and uses thereof
AU6618100A (en) Monoclonal antibodies to tacrolimus and immunoassay methods for tacrolimus
HU9800613D0 (en) Humanized anti-human fas antibody
IL145894A0 (en) Use of heparin-binding antagonists in the inhibition of bradykinin release
DE69115104D1 (de) Composition comprising at least two different antibodies or fragments thereof.
IS6143A (is) Peptíð úr TT veiruröð og einsérhæfð mótefni, sem bindast TT veirunni
NO20001051D0 (no) Monoklonale antistoffer som binder testosteron
NO20004251D0 (no) Humaniserte anti-CEA monoklonale antistoffer med høy affinitet
AU2001290801A1 (en) Peptide epitopes recognized by antigen specific cd4+ t lymphocytes